Keryx Biopharmaceuticals Receives FDA Orphan Approval For Treatment of Neuroblastoma
Keryx Biopharmaceuticals (Nasdaq: KERX) receives FDA approval for treatment of Neuroblastoma.
Not FDA Approved for Orphan Indication
Keryx Biopharmaceuticals is up close to 10% this morning.
See Some of the Top Moving Indexes Here.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.